Aortic Stenosis
Introduction
Aortic stenosis (AS) is a prevalent cardiovascular condition characterized by the progressive narrowing of the aortic valve's functional opening. This narrowing obstructs the flow of blood from the left ventricle into the aorta, leading to increased pressure and stress on the heart muscle. [1] It is the most common valvular heart disease in adults, with prevalence estimates ranging from 0.3% to 0.5% in the general population, and significantly higher rates, up to 7%, in individuals over 65 years of age. [2] The disease typically progresses with a prolonged asymptomatic phase, followed by a period of rapid health decline once symptoms manifest [3] highlighting the critical importance of early detection for effective therapeutic intervention. [1]
Biological Basis
The intricate geometry of the aortic valve is fundamental to normal cardiac structure and function, influencing blood flow dynamics and the heart's response to various stresses. [1] Aortic stenosis is understood to have a complex heritability pattern, involving contributions from multiple genes. [1] Genome-wide association studies (GWAS) have identified several genomic loci linked to AS risk and reduced aortic valve area. For instance, specific variants like rs1830321, rs10455872, chr13:50764607_C_CT, chr12:94191968_T_TG, and chr17:45013271_T_C have shown significant associations. [1] The LPA gene variant rs10455872 has been consistently associated with reduced aortic valve area. [1] Other genes and regions implicated include CELSR2/PSRC1, SH2B3, CFDP1, PALMD, TEX41, and MYH6. [4] Some genetic variants associated with AS are also linked to related conditions such as bicuspid aortic valve (BAV) and congenital cardiac septal defects. [4] Additionally, genetic factors influencing aortic root size, such as rs7543130 near CFDP1, have been found to associate with AS. [4] Beyond these, coronary artery disease (CAD) genetic risk scores also show an association with AS. [4] Research indicates that calcium signaling pathway genes like RUNX2 and CACNA1C are associated with calcific aortic valve disease [5] and APOE alleles and estrogen receptor alpha gene polymorphisms have been related to calcific valvular heart disease and aortic valve sclerosis. [6]
Clinical Relevance
Aortic stenosis poses a substantial clinical challenge due to its progressive nature and severe impact on cardiac function. The typically asymptomatic initial phase means that by the time symptoms like chest pain, shortness of breath, or fainting appear, the disease is often advanced, leading to a rapid decline in patient health. [3] This makes early detection and monitoring crucial for timely intervention. Diagnostic methods include physical examination, auscultation of heart sounds, echocardiography, and cardiac catheterization. Advances in cardiac imaging, particularly magnetic resonance imaging (MRI) with automated analysis, are improving diagnostic capabilities and the ability to differentiate between bicuspid and normal (tricuspid) aortic valves. [1] These technological advancements, combined with genetic insights, offer promising avenues for identifying individuals at high risk earlier, potentially leading to personalized management strategies and improved clinical outcomes.
Social Importance
Given its high prevalence, particularly within the aging global population, aortic stenosis represents a significant public health concern. The burden of this disease extends beyond individual health, impacting healthcare systems through the need for complex diagnostics, long-term monitoring, and often invasive surgical or transcatheter interventions. The progressive and debilitating nature of AS, if left untreated, severely diminishes quality of life and shortens lifespan. Therefore, understanding the genetic factors underlying AS is of immense social importance. This knowledge can facilitate the development of predictive tools, allowing for earlier identification of at-risk individuals, and potentially guiding preventive strategies or earlier therapeutic interventions. Large-scale genetic studies, such as those utilizing biobanks, are vital in unraveling the genetic architecture of AS, paving the way for more effective screening programs and ultimately reducing the societal impact of this debilitating heart condition. [1]
Methodological and Statistical Considerations
The genetic understanding of aortic stenosis is influenced by several methodological and statistical constraints inherent in large-scale genetic studies. Many investigations, for instance, explicitly exclude variants with minor allele frequency (MAF) below certain thresholds (e.g., MAF ≤ 0.001 or MAF < 0.001), significantly limiting the ability to detect genetic associations driven by very rare variants that can have substantial biological effects. [7] This exclusion strategy can lead to an underestimation of the full genetic architecture of aortic stenosis, as rare variants are increasingly recognized for their role in complex diseases. Furthermore, measurement errors in phenotypic assessment can bias genetic association estimates towards the null hypothesis, making it harder to identify true genetic signals. [8] For example, M-mode echocardiography, commonly used for aortic root diameter, may be less accurate and prone to underestimation when compared to two-dimensional imaging methods. [8]
Despite the utilization of large cohorts, such as the UK Biobank with tens of thousands of participants for aortic valve area or aortic diameter studies, statistical power can still be insufficient to detect modest genetic effects, particularly when there is phenotypic heterogeneity or varying study designs across meta-analyses. [1] Rigorous cohort filtering criteria, including exclusions based on genotyping call rates, sex chromosome aneuploidy, or excessive relatedness, while crucial for data quality, can also introduce selection biases that affect the overall representativeness of the studied population and potentially inflate effect sizes for certain variants. [7] The application of stringent statistical corrections, such as Bonferroni, for multiple testing also sets a high bar for significance, potentially causing true, but modest, associations to be overlooked. [9]
Generalizability and Phenotypic Nuances
A significant limitation in the current genetic research on aortic stenosis is the predominant focus on individuals of European ancestry. [1] This demographic bias severely restricts the generalizability of identified genetic associations and risk prediction models to other populations, where genetic architectures, allele frequencies, and environmental exposures can differ substantially. Studies have explicitly noted a lack of statistical power and, consequently, a failure to find significant associations in non-European ancestral subsets, highlighting this critical gap in understanding. [10] This calls for more diverse genetic studies to ensure equitable application of genetic discoveries in clinical practice.
Furthermore, the precise phenotyping of aortic stenosis and related aortic traits presents challenges that can impact interpretation. Some studies rely on proxy measures, such as planimetric assessments of aortic valve functional area obtained through automated cardiac MRI, as an indicator of valvular function. [1] While these automated approaches are efficient for large biobanks, they may not fully capture the clinical complexity, severity, or progression of aortic stenosis compared to direct clinical diagnoses. The exclusion of specific disease subtypes, such as individuals with a history of aortic aneurysm or dissection, or known/suspected bicuspid aortic valves (BAV), also limits the scope of genetic discoveries. [7] While this exclusion helps reduce heterogeneity and focuses on distinct etiologies, it means that the identified genetic factors may not fully explain the etiology of aortic stenosis in these excluded populations, which often present with different genetic underpinnings and clinical courses.
Unaccounted Factors and Remaining Knowledge Gaps
Despite significant progress in identifying genetic associations with aortic stenosis, the contributions of environmental factors and gene-environment interactions remain less comprehensively explored in the provided research. Current studies primarily focus on identifying genetic predispositions, leaving substantial gaps in understanding how lifestyle, diet, co-morbidities, or other external influences might modulate genetic risk or directly contribute to disease development and progression. A more holistic approach integrating detailed environmental data is crucial for a complete etiological picture.
Moreover, the deliberate exclusion of rare variants likely to lead to Mendelian aortopathy from genome-wide association studies, while useful for dissecting polygenic inheritance, means that the genetic landscape of monogenic forms of aortic disease is not fully captured or integrated within these broader analyses. [7] This approach limits the understanding of how common and rare genetic variations collectively contribute to the spectrum of aortic stenosis. Despite the identification of numerous genetic loci, a portion of the heritability for aortic stenosis and related aortic traits often remains "missing". [8] This missing heritability suggests that additional genetic influences, potentially from rare variants with small effect sizes, complex gene-gene interactions, or epigenetic factors not assessed in these studies, are yet to be discovered. The limited sample sizes for highly specific analyses, such as single-nucleus RNA sequencing performed on only a few individuals, further restricts the depth of understanding regarding tissue-specific and cellular mechanisms underlying the observed genetic associations. [7]
Variants
Genetic variants play a significant role in predisposing individuals to aortic stenosis (AS), a progressive calcification and stiffening of the aortic valve. These variants often influence lipid metabolism, inflammatory pathways, and the structural integrity of cardiovascular tissues.
The LPA (lipoprotein(a)) gene is central to lipid metabolism, and elevated lipoprotein(a) levels are a recognized risk factor for various cardiovascular diseases. An intronic variant, rs10455872, in the LPA gene is strongly associated with an increased risk of incident aortic stenosis, showing a hazard ratio of 1.68 per risk allele. [11] This variant also correlates with a reduced aortic valve area and contributes to a 62% increase in the odds of aortic valve calcification for every log-unit rise in plasma Lp(a) levels. [1] Unlike some other AS-associated variants, rs10455872 does not appear to be linked to bicuspid aortic valve (BAV), suggesting its primary mechanism in AS is through lipid-driven calcification rather than congenital structural defects. [4] Similarly, the TEX41 gene is implicated in aortic stenosis through variants like rs1830321. This intronic variant shows a statistically significant association with AS, bicuspid aortic valve, congenital cardiac septal defects, and a reduced aortic valve area. [4] Another variant, rs7543130, located in an intergenic region near PALMD and also listed under LINC01708, is associated with increased aortic root dimension, BAV, and congenital cardiac septal defects, suggesting a role in aortic development and structure. [4]
Genes involved in inflammatory and bone mineralization pathways are also critical contributors to calcific aortic valve stenosis. IL6 (Interleukin 6), a key pro-inflammatory cytokine, has been identified as a novel susceptibility gene for this condition. [12] Variants such as rs1800797, rs1474347, and rs2069832 within the IL6 gene can modulate its expression and activity, thereby influencing the chronic inflammatory environment that drives valve calcification. Likewise, ALPL (Alkaline Phosphatase, Liver/Bone/Kidney type) is recognized as a novel susceptibility gene for calcific aortic valve stenosis. [12] ALPL encodes tissue-nonspecific alkaline phosphatase (TNAP), an enzyme vital for bone mineralization, and its increased activity in valve tissues promotes the pathological deposition of calcium phosphate crystals. Variants like rs6696066 and rs12141569 in ALPL may alter the enzyme's function or expression, thereby influencing the calcification process. Furthermore, the NAV1 (Neuron Navigator 1) gene has emerged as a novel susceptibility gene for calcific aortic valve stenosis. [12] Its involvement in aortic valve pathology suggests roles in cellular processes such as extracellular matrix remodeling or fibroblast differentiation, with variants like rs631556, rs682112, and rs665770 potentially impacting these mechanisms.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs10455872 rs140570886 |
LPA | myocardial infarction lipoprotein-associated phospholipase A(2) measurement response to statin lipoprotein A measurement parental longevity |
| rs6702619 rs11166276 rs7543130 |
LINC01708 | aortic stenosis bulb of aorta size magnetic resonance imaging of the heart heart failure heart valve disease |
| rs1800797 | IL6, STEAP1B, IL6-AS1 | asthma level of myocilin in blood systemic lupus erythematosus aortic stenosis |
| rs7593336 rs1830321 rs2246363 |
TEX41 | aortic stenosis |
| rs72854462 | TEX41 | diastolic blood pressure red blood cell density erythrocyte count systolic blood pressure aortic stenosis |
| rs631556 rs682112 rs665770 |
IPO9-AS1, NAV1 | aortic stenosis diastolic blood pressure |
| rs1474347 rs2069832 |
IL6 | aortic stenosis |
| rs6696066 rs12141569 |
ALPL | aortic stenosis |
| rs17156153 | COX8BP - NLRP6 | HbA1c measurement aortic stenosis |
| rs1016819 rs61817383 rs2150026 |
PRRX1 | aortic stenosis |
Definition and Core Characteristics
Aortic stenosis (AS), also known as aortic valve stenosis (AVS), is a prevalent cardiovascular condition defined by the narrowing of the aortic valve's functional orifice. [1] This obstruction impedes the ejection of blood from the left ventricle, leading to increased left ventricular wall stress. [1] The disease is characterized by thickened and calcified valvular cusps, which progressively restrict blood flow. [4]
AS is the most common valvular disease in adults, with a general population prevalence estimated between 0.3% and 0.5%, rising significantly to approximately 7% in individuals over 65 years of age. [1] The natural history of adult-onset AS typically involves an extended asymptomatic period before the onset of symptoms, which is then followed by a decline in health, underscoring the importance of early detection. [1] While its exact pathogenesis remains under investigation, calcified aortic valve lesions share many features with atherosclerotic disease, including initial endothelial damage, oxidized lipid deposition, chronic inflammation, and subsequent calcification. [4]
Classification and Severity Grading
Aortic stenosis is primarily classified by its severity, commonly graded as mild, moderate, or severe. [4] This classification is critically determined by quantitative measurements of the aortic valve area and the pressure gradient across the valve. [4] Severe AS is a significant cause of morbidity and mortality, particularly in individuals over 70, where the estimated five-year survival rate for symptomatic severe AS can range from 15% to 50% without intervention like aortic valve replacement. [4]
Beyond severity, AS encompasses distinct subtypes and related conditions. Bicuspid aortic valve (BAV), the most common congenital cardiac malformation where the aortic valve has two leaflets instead of the typical three, is a significant subtype that accelerates the development of AS by decades. [4] Imaging techniques are used for comprehensive categorization of BAV leaflet morphology. [13] "Calcific aortic valve disease" is often used interchangeably with calcific AS, highlighting the pathological process of calcification. [12] Furthermore, "aortic valve thickening" is recognized as a precursor condition that carries a risk for the future development of AS. [14]
Diagnostic Approaches and Measurement Criteria
The diagnosis of aortic stenosis relies on a multifaceted approach, traditionally involving physical examination, auscultation for characteristic murmurs, echocardiography, and in some cases, cardiac catheterization or surgical findings. [1] Echocardiography is fundamental for measuring key diagnostic criteria such as the aortic valve area and the pressure gradient across the valve. [4] Advanced imaging modalities, including magnetic resonance imaging (MRI), are increasingly utilized, with software-based methods providing planimetric measures of the functional aortic valve area and aiding in distinguishing between bicuspid and normal (tricuspid) aortic valves. [1]
Operational definitions for calcification, a hallmark of AS, involve imaging thresholds such as a calcified lesion being defined by an area of at least three connected pixels with CT attenuation exceeding 130 Hounsfield Units. [15] Beyond direct valve assessment, related cardiac structures are also measured; for instance, aortic root diameter is assessed, though M-mode echocardiography measurements may underestimate its true size compared to two-dimensional imaging. [8] These precise measurement approaches and criteria are essential for accurate diagnosis, severity grading, and monitoring the progression of aortic stenosis. [4]
Clinical Presentation and Disease Progression
Aortic stenosis (AS) is characterized by a narrowing of the functional orifice of the aortic valve, leading to an obstruction of blood ejection from the left ventricle and increased wall stress .
Genetic Predisposition and Heritability
Aortic stenosis exhibits a complex heritability pattern, suggesting that multiple genes contribute to an individual's susceptibility. [1] Large-scale genome-wide association studies (GWAS) have been instrumental in identifying novel genomic loci linked to the condition. These studies have revealed that a polygenic risk, encompassing numerous common genetic variants, contributes to the overall risk of developing aortic stenosis. For instance, a genetic risk score for coronary artery disease (CAD-GRS) has shown an association with aortic stenosis risk, highlighting shared genetic underpinnings between these cardiovascular conditions. [4]
Several specific genetic variants have been identified that directly influence the development of aortic stenosis. The LPA variant rs10455872, for example, is consistently associated with a higher risk of aortic stenosis and reduced aortic valve area. [1] Other variants, such as those near PALMD on chromosome 1p21 and in TEX41 on chromosome 2q22, have also been discovered and replicated as common aortic stenosis variants. [4] Additionally, variants in genes like CELSR2/PSRC1 and SH2B3 have been linked to the condition, alongside calcium signaling pathway genes such as RUNX2 and CACNA1C, which are specifically associated with calcific aortic valve disease. [4] Beyond common variants, rare genetic mutations can also contribute to aortic stenosis. A rare missense variant in MYH6, for instance, has been identified in association with aortic stenosis. [4] Furthermore, polymorphisms in genes like apolipoprotein E and the estrogen receptor alpha gene have been implicated in calcific valvular heart disease and aortic valve sclerosis, respectively, particularly in postmenopausal women. [11] These genetic factors influence the structural integrity and calcification processes of the aortic valve, predisposing individuals to its narrowing and dysfunction.
Congenital Valve and Structural Heart Abnormalities
Congenital abnormalities of the aortic valve are significant predisposing factors for the development of aortic stenosis. Bicuspid aortic valve (BAV), a condition where the aortic valve has two leaflets instead of the usual three, is recognized as a major risk factor for aortic stenosis. [4] Certain genetic variants, including the rare MYH6 variant and those on chromosome 1p21, are strongly associated with BAV and congenital cardiac septal defects. [4] It is postulated that the increased risk of aortic stenosis conferred by these specific variants may be mediated through their primary effect on BAV development. [4]
The presence of other congenital heart defects can also increase the susceptibility to aortic stenosis later in life. Variants associated with aortic stenosis have been linked to congenital cardiac septal defects, such as atrial septal defect and ventricular septal defect. [4] These structural anomalies can alter blood flow dynamics and place abnormal stress on the developing or functioning aortic valve, thereby accelerating degenerative processes and the onset of stenosis.
Age-Related Degeneration and Comorbid Conditions
Advancing age is a primary and independent risk factor for aortic stenosis, with prevalence rates significantly increasing in older populations, reaching up to 7% in individuals over 65 years of age. [1] This age-related increase is largely attributed to degenerative calcification of the aortic valve leaflets, a process that can initiate with seemingly "benign" aortic valve thickening and progress over time to severe stenosis. [14] The gradual wear and tear on the valve, coupled with chronic inflammation and lipid deposition, contribute to the progressive stiffening and calcification characteristic of adult-onset aortic stenosis.
Several cardiovascular comorbidities and related structural changes also contribute to the pathogenesis of aortic stenosis. Coronary artery disease (CAD) shares genetic links with aortic stenosis, and specific variants associated with AS have also been implicated in CAD. [4] Abnormalities in aortic root dimension, such as an increased aortic root diameter, are also associated with a higher risk of aortic stenosis. [4] Furthermore, genetic variants linked to aortic root size have also shown associations with markers of generalized vascular stiffening, such as carotid intima-media thickness, suggesting a broader systemic predisposition to vascular and valvular pathology. [4]
Biological Background of Aortic Stenosis
Aortic stenosis (AS) is a prevalent cardiovascular condition characterized by the narrowing of the aortic valve's functional opening, which impedes the ejection of blood from the left ventricle and increases myocardial wall stress. [1] This progressive disease is the most common valvular heart condition in adults, affecting an estimated 0.3% to 0.5% of the general population, with prevalence rising significantly to 7% in individuals over 65 years of age. [2] The natural course of adult-onset AS often involves an extended asymptomatic phase, followed by a decline in health once symptoms manifest. [3]
Pathophysiology and Cellular Mechanisms
The fundamental pathophysiological process in aortic stenosis involves the calcification of the aortic valve, a complex cellular mechanism that resembles bone formation . [11], [16] Valvular interstitial cells play a critical role in this process, with their calcification being significantly influenced by the MAPK/ERK signaling pathway. [17] Research indicates that inhibiting the MAPK-Erk pathway can attenuate the progression of aortic valve disease. [18] Additionally, the biomolecule Galectin-3 has been implicated in the development of calcific aortic valve stenosis, suggesting its involvement in the disease's cellular pathology. [19]
Further contributing to the disease, defects in the exocyst-cilia machinery have been identified as a cause of bicuspid aortic valve disease and aortic stenosis. [20] The primary cilium, a cellular organelle, is crucial for various signaling pathways, including Notch signaling, which is essential for proper development and cellular differentiation. [21] The protein _Arl13b_ and the exocyst complex work synergistically in the process of ciliogenesis, underscoring the importance of these structures in maintaining valvular health. [22] Dysregulation of the Wnt/b-catenin, Notch, and BMP signaling pathways has also been observed in aortic endothelial cells, highlighting their potential role in valvular pathology. [23]
Genetic Predisposition and Molecular Regulation
Aortic stenosis exhibits a complex heritability pattern, with multiple genes contributing to its development. [1] Genome-wide association studies (GWAS) have identified several genomic loci linked to the disease. [1] Specific genetic variants in calcium signaling pathway genes, such as _RUNX2_ and _CACNA1C_, are associated with calcific aortic valve disease. [5] Furthermore, genetic variants related to low-density lipoprotein cholesterol levels are associated with aortic valve calcium accumulation and the incidence of AS [24] and specific alleles of _Apolipoprotein E_ are linked to calcific valvular heart disease. [6]
Genetic polymorphisms also influence the composition of aortic valves, with variants in the _Oestrogen receptor α_ gene related to aortic valve sclerosis in postmenopausal women [25] and other genetic factors affecting the amount of calcium-deficient hexagonal hydroxyapatite in aortic valves. [26] Regulatory variants in _TCF7L2_, a transcription factor, are associated with thoracic aortic aneurysm, and its increased mRNA expression can activate the Wnt/b-catenin pathway in the endothelium. [23] Other genes like _HMGA2_, which encodes a transcriptional regulating factor, and _PDE3A_, expressed in aortic tissue, have been associated with aortic root diameter. [8] A variant intronic to _CFDP1_ is also associated with AS, and a correlated variant, *rs4888378*, is linked to carotid intima-media thickness. [4]
Signaling Pathways and Developmental Aspects
The Wnt/b-catenin signaling pathway is a highly conserved regulatory network crucial for various developmental processes, including cell proliferation, migration, polarity, and apoptosis. [23] Dysregulation of this pathway is implicated in numerous disorders, including cardiovascular conditions like restenosis. [23] _TCF7L2_ plays a role in vascular development and regulates vascular smooth muscle cell (VSMC) plasticity . [23], [27] The activation of the Wnt/b-catenin pathway, potentially through epigenetic silencing of Wnt inhibitors, is also observed in abdominal aortic aneurysms. [23]
In the context of vascular health, _WT1_ (Wilms Tumor 1) is recognized for its involvement in cardiac development and disease. [28] The glycocalyx of vascular smooth muscle cells mediates shear stress-induced contractile responses via the Rho pathway. [29] Additionally, reactive oxygen species (ROS) can downregulate _MYPT1_ in smooth muscle cells, contributing to aberrant contractility seen in atherosclerosis. [30] Telomerase activity, which is upregulated in the aorta of spontaneous hypertensive rats, is critical for vascular remodeling, as its downregulation can arrest VSMC proliferation and induce apoptosis. [8]
Tissue-Level Changes and Systemic Impact
The geometry of the aortic valve is fundamental to cardiac structure and function, influencing fluid dynamics, the heart's response to stress, and the development of valvular pathology. [31] In AS, the obstruction of blood ejection from the left ventricle leads to increased wall stress. [1] A significant predisposing factor for AS is a bicuspid aortic valve (BAV), a congenital defect where the valve has two leaflets instead of the usual three . [20], [32] BAV is often associated with aortopathy, suggesting a shared developmental origin or common pathogenic mechanisms. [4]
Genetic variants, such as *rs7543130[A]* on chromosome 1p21, are linked to increased aortic root dimension, indicating a genetic influence on the structural integrity of the aorta. [4] Systemically, AS is linked to arterial stiffness, with genetic variants in _Fibrillin-1_, angiotensin-converting enzyme, angiotensin II type 1 receptor, _Beta-adrenergic receptor_ genes, and _Endothelin_ gene all influencing aortic stiffness . [33], [34], [35], [36], [37] Common genetic variation in the 3'-_BCL11B_ gene desert is also associated with carotid-femoral pulse wave velocity and an elevated risk of cardiovascular disease. [38] These systemic connections highlight that AS is not merely an isolated valve disorder but can be part of a broader cardiovascular disease spectrum, including associations with abdominal aortic aneurysms . [39], [40]
Valvular Remodeling and Calcification Pathways
Aortic stenosis is characterized by progressive calcification and remodeling of the aortic valve leaflets, processes driven by complex cellular and molecular pathways. The MAPK/ERK pathway plays a significant role in valvular interstitial cell (VIC) calcification, with studies demonstrating that inhibiting this pathway can attenuate aortic valve disease progression in animal models. [18] This suggests that dysregulation of intracellular signaling cascades, involving receptor activation and downstream phosphorylation events, contributes directly to the pathological mineralization of valve tissue. Furthermore, specific genes involved in calcium signaling, such as RUNX2 and CACNA1C, have been associated with calcific aortic valve disease, highlighting the genetic predisposition and molecular machinery governing calcium deposition. [5] The protein Galectin-3 has also been identified as a contributor to calcific aortic valve stenosis, suggesting its involvement in extracellular matrix remodeling and inflammatory processes that facilitate calcification. [19]
Beyond direct calcification, the phenotype of vascular smooth muscle cells (VSMCs) is critical in aortic remodeling. HDAC9 (Histone Deacetylase 9) is implicated in atherosclerotic aortic calcification and significantly influences VSMC phenotype. [41] This indicates that epigenetic regulatory mechanisms, specifically histone deacetylation, can alter gene expression profiles in VSMCs, driving them towards a more osteogenic or calcifying phenotype. Such alterations contribute to the stiffening and dysfunction of the aortic valve, representing a key disease-relevant mechanism that could serve as a therapeutic target.
Developmental Signaling and Cellular Plasticity
Several evolutionarily conserved signaling pathways that govern development also play critical roles in aortic valve health and disease. The Wnt/β-catenin pathway is fundamental for processes like cell proliferation, migration, polarity, and apoptosis, and its dysregulation is implicated in various cardiovascular disorders. [23] In the context of aortic disease, TCF7L2 (Transcription Factor 7-Like 2), a key component of the Wnt/β-catenin pathway, regulates VSMC plasticity in both GATA6-dependent and -independent fashions, impacting the cellular environment of the aortic wall. [27] Activation of the Wnt/β-catenin pathway, often accompanied by increased TCF7L2 mRNA expression, has been observed in aortic endothelial cells, suggesting its involvement in the initiation and progression of aortic pathology. [23]
Alongside Wnt, the Notch and BMP (Bone Morphogenetic Protein) pathways are also critical developmental signaling cascades, with dysregulation of these networks found in aortic endothelial cells from individuals with aortic aneurysms. [42] These pathways engage in complex crosstalk, influencing cell fate and function. The primary cilium, a cellular organelle, acts as a signaling hub and is involved in Notch signaling, mediating processes like epidermal differentiation. [21] Defects in the exocyst-cilia machinery can lead to conditions such as bicuspid aortic valve disease and aortic stenosis, underscoring the importance of these cellular structures in the proper development and long-term function of the aortic valve . Transcription factors, which are key regulators of gene expression, form intricate networks; for instance, ELF1, ETS2, RUNX1, and STAT5 have been studied for their binding patterns in human aortic tissue. [43] These transcription factors can interact synergistically or antagonistically to modulate the aortic phenotype, influencing processes like VSMC differentiation, inflammation, and extracellular matrix turnover.
Epigenetic mechanisms, such as DNA methylation and histone modifications, contribute to contextual tissue and cell-type-specific functions by altering gene accessibility without changing the underlying DNA sequence. [23] A notable example is the epigenetic silencing of sclerostin, an inhibitor of the Wnt pathway, which can lead to activation of Wnt/β-catenin signaling. [44] This highlights how feedback loops and regulatory mechanisms, including post-translational protein modifications and allosteric control, can fine-tune pathway activity, and their dysregulation can contribute to disease by altering the balance of cellular processes in the aortic valve.
Interconnected Signaling Networks
The progression of aortic stenosis involves a highly integrated network of pathways rather than isolated molecular events. Pathway crosstalk is a fundamental aspect of this systems-level integration, where different signaling cascades influence one another to produce a coordinated cellular response. For example, the Wnt/β-catenin pathway interacts with GATA6 to regulate VSMC plasticity, demonstrating how distinct signaling axes converge to control critical cellular behaviors in the aortic wall. [27] Network analysis tools are utilized to investigate how genetic loci associated with aortic pathology can be connected into complex networks through intermediate nodes and interactions, providing hypotheses for how these loci might act in concert. [39]
These network interactions reveal a hierarchical regulation where multiple pathways contribute to emergent properties of the tissue, such as calcification or remodeling. While specific metabolic pathways directly linking to aortic stenosis are not extensively detailed in the provided context, metabolic regulation and flux control are integral to cellular function and are inherently intertwined with signaling networks. Dysregulation in these integrated systems leads to compensatory mechanisms that, over time, can exacerbate disease progression, making the identification of key nodes within these networks crucial for developing therapeutic targets.
Epidemiological Landscape and Temporal Trends
Aortic stenosis (AS) is recognized as the most prevalent valvular disease in adult populations, with significant epidemiological patterns observed across different age groups and geographic regions. General population prevalence estimates range from 0.3% to 0.5%, but this figure rises sharply in older individuals, reaching up to 7% in those over 65 years of age. [2] The natural history of adult-onset AS is often characterized by a prolonged asymptomatic phase, followed by a decline in health once symptoms manifest, underscoring the importance of early detection. [3] Longitudinal studies, such as a nation-wide investigation in Sweden, have tracked temporal trends in both the incidence and prognosis of AS, revealing dynamic changes over time. [45] Similarly, the AGES–Reykjavík study has provided crucial insights into the prevalence of AS among the elderly in Iceland and offered projections for future decades, contributing to a broader understanding of disease burden and healthcare planning. [46]
Further epidemiological research, including a meta-analysis and modeling study, has focused on AS in the elderly population to determine disease prevalence and estimate the number of potential candidates for transcatheter aortic valve replacement, highlighting the growing clinical relevance of this condition. [47] These studies collectively establish a clear demographic profile for AS, predominantly affecting older adults, and emphasize the need for continued monitoring of its incidence and progression within aging populations. The consistent findings across various cohorts underscore a shared global challenge in managing AS, driven by increasing life expectancies.
Large-Scale Cohort Investigations and Genetic Insights
Large-scale cohort studies and biobank initiatives have been instrumental in unraveling the genetic architecture and population-level associations of aortic stenosis. The UK Biobank, a prominent resource, has facilitated extensive research, including cardiac imaging of aortic valve area in over 34,000 participants. [1] These studies have not only revealed novel genetic associations but also identified shared genetic comorbidities with various disease phenotypes, providing a comprehensive view of AS within a broader health context. [1] Another significant endeavor leveraged deep learning techniques to analyze genetic data from the UK Biobank, enabling detailed genetic analyses of the human thoracic aorta after stringent participant exclusions based on genotyping quality, relatedness, and pre-existing aortic conditions. [7]
Beyond the UK Biobank, Icelandic cohorts, particularly those managed by deCODE genetics, have contributed substantially to AS research, utilizing a vast biobank established in 1996 and an extensive genealogical database comprising over 349,000 population controls. [48] These resources have been pivotal in genome-wide association studies (GWAS) that identified new genetic loci linked to AS, employing rigorous case-control analyses adjusted for demographic factors. [4] Several variants, such as rs1830321 and rs10455872 in the LPA gene, have shown significant associations with reduced aortic valve area, consistent with their established link to a higher risk of AS. [1] Other major cohorts like the Multi-Ethnic Study of Atherosclerosis (MESA), Framingham Heart Study (FHS), Malmö Diet and Cancer Study (MDCS), Copenhagen City Heart Study (CCHS), and Heinz Nixdorf Recall Study (HNR) have also contributed to the discovery and replication of genetic associations with valvular calcification and AS. [11]
Population Diversity and Methodological Rigor
Population studies on aortic stenosis consistently incorporate diverse cohorts and rigorous methodologies to ensure the representativeness and generalizability of their findings. Cross-population comparisons are crucial, with many genetic studies focusing on participants of European ancestry, often confirmed through techniques like principal component analysis to control for population stratification. [4] However, studies like MESA have actively included multi-ethnic groups, such as African-American, Chinese-American, and Hispanic-American participants, to investigate ancestry-specific effects and enhance the broader applicability of genetic discoveries. [11] Geographic variations in AS prevalence and genetic predispositions are also explored, drawing data from cohorts in countries including the United States, Sweden, Denmark, and Iceland. [11]
Methodologically, these studies employ sophisticated designs to minimize confounding and bias. Genome-wide association studies typically involve meticulous case-control matching based on demographic factors like sex, age, and ancestry, sometimes utilizing incremental tolerances to achieve desired control-to-case ratios. [4] Advanced statistical models, such as logistic regression and SAIGE, are used, with adjustments for covariates including age, sex, genetic principal components, and array version. [4] Furthermore, strict quality control measures, including excluding individuals with poor genotyping call rates, sex chromosome aneuploidy, excessive relatedness, or specific pre-existing conditions, are routinely applied to ensure data integrity. [7] The consistent reporting of genomic control values within accepted ranges further attests to the robustness of these association analyses, ensuring minimal confounding. [40] All studies adhere to ethical guidelines, obtaining informed consent from participants and approval from relevant ethics committees. [4]
Frequently Asked Questions About Aortic Stenosis
These questions address the most important and specific aspects of aortic stenosis based on current genetic research.
1. My parents have heart issues; does that mean I'll get aortic stenosis too?
Yes, there's a good chance. Aortic stenosis has a complex genetic basis, meaning it can run in families. If your parents have it, you might have inherited some of the genetic factors that increase your risk. Specific genes like LPA and others are known to contribute to this condition.
2. Why is aortic stenosis more common as I get older?
Aortic stenosis is indeed much more prevalent in older adults, affecting up to 7% of individuals over 65. While the exact reasons are complex, genetic factors, including certain APOE alleles and estrogen receptor alpha gene variations, play a role in the age-related calcification and hardening of the valve that leads to stenosis.
3. If I feel fine, could I still have aortic stenosis?
Absolutely. Aortic stenosis often has a long period where you don't feel any symptoms at all. By the time symptoms like chest pain or shortness of breath appear, the disease can be quite advanced. This is why early detection, even when asymptomatic, is so important for timely intervention.
4. Why do some people get severe aortic stenosis while others don't?
It's a combination of genetics and other factors. Some individuals inherit specific gene variants, like those in LPA or calcium signaling genes like RUNX2, that make them more prone to developing the condition or experiencing faster progression. Environmental influences also play a role, but genetics significantly contribute to individual differences in severity.
5. I have a family history of heart disease; am I at higher risk for this?
Yes, you could be. Genetic risk factors for other heart conditions, such as coronary artery disease (CAD), have been linked to an increased risk for aortic stenosis. This suggests some shared genetic pathways or predispositions. Discussing your family history with your doctor can help assess your overall risk.
6. Would a DNA test help me know my risk for aortic stenosis?
Potentially, yes. Genome-wide studies have identified several genetic markers associated with aortic stenosis risk and reduced valve area. While not a definitive diagnosis, knowing if you carry certain variants, like those in the LPA gene, could indicate a higher predisposition and help guide earlier monitoring or preventive discussions with your doctor.
7. Can I do anything to prevent aortic stenosis, even with a family history?
While you can't change your genes, understanding your genetic predisposition can guide personalized strategies. Although specific lifestyle interventions for preventing AS aren't fully detailed, early identification through genetic insights allows for closer monitoring and potentially earlier interventions to manage the disease's progression.
8. Could my child inherit a risk for this heart problem?
Yes, there's a possibility. Some genetic variants associated with aortic stenosis are also linked to congenital heart conditions, such as bicuspid aortic valve (BAV) or septal defects, which can be inherited. If there's a family history of these conditions, it's worth discussing with a pediatrician or genetic counselor.
9. I hear calcium is bad for my heart; does that affect aortic stenosis?
It's more complex than just dietary calcium being "bad." Genes involved in calcium signaling, such as RUNX2 and CACNA1C, are associated with calcific aortic valve disease. This means your genetic makeup influences how your body handles calcium in the heart valve, leading to hardening, rather than just calcium in your diet directly causing the issue.
10. If I have this, will it definitely get worse quickly?
Not necessarily "quickly" at first. Aortic stenosis typically has a long phase where you have no symptoms and the progression is slow. However, once symptoms do appear, the disease can progress rapidly. That's why consistent monitoring and early intervention are crucial to manage its course effectively.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Cordova-Palomera A, et al. "Cardiac Imaging of Aortic Valve Area from 34,287 UK Biobank Participants Reveal Novel Genetic Associations and Shared Genetic Comorbidity with Multiple Disease Phenotypes." Circ Genom Precis Med, 2020.
[2] Gulino, S, Di Landro A, Indelicato A. "Aortic stenosis: epidemiology and pathogenesis." Percutaneous Treatment of Left Side Cardiac Valves, Springer, 2018, pp. 245–252.
[3] Kelly, T. A., et al. "Comparison of outcome of asymptomatic to symptomatic patients older than 20 years of age with valvular aortic stenosis." Circulation, vol. 80, no. 1, 1989, pp. 110–115.
[4] Helgadottir A, et al. "Genome-wide analysis yields new loci associating with aortic valve stenosis." Nat Commun, vol. 9, 2018.
[5] Guauque-Olarte, S., et al. "Calcium signaling pathway genes RUNX2 and CACNA1C are associated with calcific aortic valve disease clinicalperspective." Circ. Cardiovasc. Genet., vol. 8, 2015, pp. 812–822.
[6] Novaro, G. M., et al. "Association between apolipoprotein E alleles and calcific valvular heart disease." Circulation, vol. 108, 2003, pp. 1804–1808.
[7] Pirruccello, J. P. et al. "Deep learning enables genetic analysis of the human thoracic aorta." Nat Genet, 2021.
[8] Vasan, R. S. et al. "Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data." JAMA, 2009.
[9] van 't Hof, F. N., et al. "Shared Genetic Risk Factors of Intracranial, Abdominal, and Thoracic Aneurysms." Journal of the American Heart Association, vol. 5, no. 7, 2016, pp. e003254.
[10] Palmer, M. R., et al. "Loci identified by a genome-wide association study of carotid artery stenosis in the eMERGE network." Genetic Epidemiology, vol. 44, no. 7, 2020, pp. 696-709.
[11] Thanassoulis G, et al. "Genetic associations with valvular calcification and aortic stenosis." N Engl J Med, vol. 368, no. 6, 2013, pp. 503-12.
[12] Theriault, S et al. "A transcriptome-wide association study identifies PALMD as a susceptibility gene for calcific aortic valve stenosis." Nat Commun, 2017.
[13] Murphy, IG et al. "Comprehensive 4-stage categorization of bicuspid aortic valve leaflet morphology by cardiac MRI."
[14] Cosmi JE, Kort S, Tunick PA, et al. "The risk of the development of aortic stenosis in patients with “benign” aortic valve thickening." Arch Intern Med, vol. 162, no. 20, 2002, pp. 2345-47.
[15] O'Donnell, CJ et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Med Genet, 2007.
[16] Rajamannan, N. M., et al. "Calcific aortic stenosis: from bench to the bedside--emerging clinical and cellular concepts." Heart, vol. 89, 2003, pp. 801–805.
[17] Gu, X., and K. S. Masters. "Role of the MAPK/ERK pathway in valvular interstitial cell calcification." Am J Physiol Heart Circ Physiol, vol. 296, 2009, H1748–H1757.
[18] Munjal, C., et al. "Inhibition of MAPK-Erk pathway in vivo attenuates aortic valve disease processes in Emilin1-deficient mouse model." Physiol Rep, vol. 5, 2017, e13152.
[19] Sadaba, J. R., et al. "Role for Galectin-3 in Calcific Aortic Valve Stenosis." J Am Heart Assoc, vol. 5, 2016, e004360.
[20] Fulmer, D. et al. "Defects in the Exocyst-Cilia Machinery Cause Bicuspid Aortic Valve Disease and Aortic Stenosis." Circulation, 2019.
[21] Ezratty, E. J., et al. "A role for the primary cilium in Notch signaling and epidermal differentiation during skin development." Cell, vol. 145, 2011, pp. 1129–1141.
[22] Seixas, C., et al. "Arl13b and the exocyst interact synergistically in ciliogenesis." Mol Biol Cell, vol. 27, 2016, pp. 308–320.
[23] Roychowdhury, T., et al. "Regulatory variants in TCF7L2 are associated with thoracic aortic aneurysm." The American Journal of Human Genetics, vol. 108, no. 7, 2021, pp. 1269-1279.
[24] Smith, J. G., et al. "Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis." JAMA, vol. 312, 2014, p. 1764.
[25] Nordström, P., et al. "Oestrogen receptor α gene polymorphism is related to aortic valve sclerosis in postmenopausal women." J Intern Med, vol. 254, 2003, pp. 140–146.
[26] Ortlepp, J. R., et al. "The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis." Eur Heart J, vol. 25, 2004, pp. 514–522.
[27] Srivastava, R., et al. "TCF7L2 (Transcription Factor 7-Like 2) Regulation of GATA6 (GATA-Binding Protein 6)-Dependent and -Independent Vascular Smooth Muscle Cell Plasticity and Intimal Hyperplasia." Arterioscler. Thromb. Vasc. Biol., vol. 39, 2019, pp. 250–262.
[28] Duim, S. N., et al. "WT1 in cardiac development and disease." Wilms Tumor, edited by M. M. van den Heuvel-Eibrink, Brisbane, 2016.
[29] Kang, H., et al. "Vascular smooth muscle cell glycocalyx mediates shear stress-induced contractile responses via a Rho." Lab Invest, vol. 93, 2013, p. 422.
[30] Cheng, J-C., et al. "ROS-mediated downregulation of MYPT1 in smooth muscle cells: a potential mechanism for the aberrant contractility in atherosclerosis." Lab Invest, vol. 93, 2013, p. 422.
[31] Thubrikar, M. J. The Aortic Valve. CRC Press, 1990.
[32] Roberts, W. C., and J. M. Ko. "Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation." Circulation, vol. 111, 2005, pp. 920–925.
[33] Benetos, A., et al. "Influence of angiotensin II type 1 receptor polymorphism on aortic stiffness in never-treated hypertensive patients." Hypertension, vol. 26, 1995, pp. 44–47.
[34] Benetos, A., et al. "Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients." Circulation, vol. 94, 1996, pp. 698–703.
[35] Chen, W., et al. "Beta-adrenergic receptor genes are associated with arterial stiffness in black and white adults: the Bogalusa Heart Study." Am J Hypertens, vol. 20, 2007, pp. 1251–1257.
[36] Medley, T. L., et al. "Fibrillin-1 genotype is associated with aortic stiffness and disease severity in patients with coronary artery disease." Circulation, vol. 105, 2002, pp. 810–815.
[37] Lajemi, M., et al. "Endothelin gene variants and aortic and cardiac structure in never-treated hypertensives." Am J Hypertens, vol. 14, 2001, pp. 755–760.
[38] Mitchell, G. F., et al. "Common genetic variation in the 3'-BCL11B gene desert is associated with carotid-femoral pulse wave velocity and excess cardiovascular disease risk: the AortaGen Consortium." Circ Cardiovasc Genet, vol. 5, 2012, pp. 81–90.
[39] Jones, G. T., et al. "Meta-Analysis of Genome-Wide Association Studies for Abdominal Aortic Aneurysm Identifies Four New Disease-Specific Risk Loci." Circ Res, vol. 120, 2017, pp. 341–353.
[40] Ashvetiya, T., et al. "Identification of novel genetic susceptibility loci for thoracic and abdominal aortic aneurysms via genome-wide association study using the UK Biobank Cohort." PLoS One, 2021.
[41] Malhotra, R., et al. "HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype." Nat Genet, vol. 51, no. 12, 2019, pp. 1656-1663.
[42] Kostina, A., et al. "Notch, BMP and WNT/b-catenin network is impaired in endothelial cells of the patients with thoracic aortic aneurysm." Atheroscler. Suppl., vol. 35, 2018, pp. e6–e13.
[43] Pahl, M. C., et al. "Transcriptional (ChIP-Chip) analysis of ELF1, ETS2, RUNX1 and STAT5 in human abdominal aortic aneurysm." Int J Mol Sci, vol. 16, no. 5, 2015, pp. 11229–11246.
[44] Krishna, S. M., et al. "Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis." Arterioscler. Thromb. Vasc. Biol., vol. 37, no. 3, 2017, pp. 553–566.
[45] Martinsson, A., et al. "Temporal trends in the incidence and prognosis of aortic stenosis: a nation-wide study of the Swedish." Heart, vol. 101, no. 13, 2015, pp. 1045-1050.
[46] Danielsen, R., et al. "The prevalence of aortic stenosis in the elderly in Iceland and predictions for the coming decades: the AGES–Reykjavík study." Int J Cardiol, 2014.
[47] Osnabrugge, R.L.J., et al. "Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study." J Am Coll Cardiol, 2013.
[48] Bjornsson, T et al. "A rare missense mutation in MYH6 associates with non-syndromic coarctation of the aorta." Eur Heart J, 2018.